MM
Arcturus Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ARCT-154 (V-0216) | COVID-19 (Primary Series & Boosters) | Approved |
| ARCT-154 (Bivalent) | COVID-19 | Phase 1/2 |
| ARCT-2301 | Cystic Fibrosis (CFTR correction) | Phase 1b |
| ARCT-032 | Cystic Fibrosis (inhaled mRNA) | Phase 1 |
| ARCT-810 | Ornithine Transcarbamylase (OTC) Deficiency | Phase 1/2 |
| ARCT-030 | Ornithine Transcarbamylase (OTC) Deficiency | Preclinical |
| LUNAR-COV19 (ARCT-021) | COVID-19 | Phase 1/2 |
| ARCT-185 | Influenza (Seasonal) | Preclinical |
Leadership Team at Arcturus Therapeutics
JE
Joseph E. Payne
President, Chief Executive Officer, Director
PC
Pad Chivukula, Ph.D.
Chief Scientific Officer, Chief Operating Officer, Director
AS
Andy Sassine, CFA
Chief Financial Officer
SA
Steve A. Hughes, M.D.
Chief Medical Officer
PC
Peter C. Farrell, Ph.D., Sc.D.
Co-Chairperson of the Board
KP
K. Peony Yu, M.D.
Senior Vice President, Clinical Development
PL
Patrick L. J. M. B. C. (Bert) Laclé
Senior Vice President, Technical Operations
JD
John D. Gargiulo
Senior Vice President, General Counsel, Corporate Secretary
DR
Dimitris Rekkas
Vice President, Quality
E(
Edward (Eddie) J. Sullivan, Ph.D.
Co-founder, former President & COO